REQUEST A DEMO
Total
USD $0.00
Search more companies

Rex Pharmaceuticals OOD (Рекс Фармасютикълс ООД) (Bulgaria)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers | Other Miscellaneous Nondurable Goods Merchant Wholesalers
Full name: Rex Pharmaceuticals OOD Profile Updated: September 09, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Rex Pharmaceuticals OOD (Рекс Фармасютикълс ООД) is a company in Bulgaria, with a head office in Sofia. It operates in the Drugs and Druggists' Sundries Merchant Wholesalers industry. It was established on December 30, 2009. It currently has a total number of 2 (2024) employees. In its most recent financial highlights, the company reported a net sales revenue drop of 63.31% in 2024. Its’ total assets recorded a negative growth of 58.06%. In, 2024, the company’s net profit margin increased by 4.37%.

Headquarters
Gradina, Bul./Ul. Simeonovsko Shose 110, Bl. 12, ET. 4, Ap. 16
Sofia; Sofia - city; Postal Code: 1700

Contact Details: Purchase the Rex Pharmaceuticals OOD (Рекс Фармасютикълс ООД) report to view the information.

Basic Information
Total Employees:
Purchase the Rex Pharmaceuticals OOD (Рекс Фармасютикълс ООД) report to view the information.
Registered Capital:
Purchase the Rex Pharmaceuticals OOD (Рекс Фармасютикълс ООД) report to view the information.
Financial Auditors:
Purchase the Rex Pharmaceuticals OOD (Рекс Фармасютикълс ООД) report to view the information.
Incorporation Date:
December 30, 2009
Key Executives
Purchase this report to view the information.
Manager
Ownership Details
Purchase this report to view the information.
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Rex Pharmaceuticals OOD (Рекс Фармасютикълс ООД) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
-63.31%▼
Total Operating Revenue
-63.29%▼
Operating Profit
2.13%▲
EBITDA
7.53%▲
Net Profit/Loss for the Period
-33.2%▼
Total Assets
-58.06%▼
Total Equity
-39.93%▼
Operating Profit Margin
7.01%▲
Net Profit Margin
4.37%▲
Return on Equity (ROE)
10.07%▲

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?